ACROMEGALY
Clinical trials for ACROMEGALY explained in plain language.
Never miss a new study
Get alerted when new ACROMEGALY trials appear
Sign up with your email to follow new studies for ACROMEGALY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New study tracks Octreotide's Real-World impact on acromegaly over two years
Disease control Recruiting nowThis study follows 200 people with acromegaly who are using octreotide subcutaneous depot, a medication that helps control hormone levels. Researchers will monitor safety and effectiveness for up to two years in everyday clinical practice, not a controlled lab setting. The goal i…
Matched conditions: ACROMEGALY
Sponsor: Camurus AB • Aim: Disease control
Last updated Jul 01, 2026 23:00 UTC
-
New shot every 3 months could ease acromegaly treatment
Disease control Recruiting nowThis phase 3 trial tests a new long-acting version of the drug octreotide (Debio 4126) for people with acromegaly, a condition caused by too much growth hormone. The drug is given as a shot every 12 weeks, instead of the usual monthly injections. The study will compare it to a pl…
Matched conditions: ACROMEGALY
Phase: PHASE3 • Sponsor: Debiopharm International SA • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug combo aims to tame acromegaly hormone levels
Disease control Recruiting nowThis phase 2 trial tests whether adding ALXN2420 (a growth hormone blocker) to standard acromegaly treatment can lower IGF-1 levels more than placebo. About 60 adults with acromegaly who are already on a stable dose of somatostatin analogs will receive either ALXN2420 or placebo …
Matched conditions: ACROMEGALY
Phase: PHASE2 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New drug MAR002 takes first step toward treating acromegaly
Disease control Recruiting nowThis Phase 1 trial tests the safety of a new drug called MAR002 in 45 healthy men. Participants receive either MAR002 or a placebo by injection. The goal is to see if it's safe and how the body processes it, before testing it in people with acromegaly.
Matched conditions: ACROMEGALY
Phase: PHASE1 • Sponsor: Marea Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Can a newer drug prevent spine fractures in acromegaly patients?
Disease control Recruiting nowThis study looks at whether the drug Pasireotide LAR can reduce the risk of spine fractures in people with acromegaly better than another drug, Pegvisomant. Acromegaly is a condition where too much growth hormone weakens bones, leading to painful fractures. Researchers will follo…
Matched conditions: ACROMEGALY
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Disease control
Last updated Jun 26, 2026 18:12 UTC
-
New PET scan aims to spot tiny brain tumors that standard MRI misses
Diagnosis Recruiting nowThis early study tests a special PET/MRI scan using a radioactive tracer called FET to find small pituitary tumors that don't show up on regular MRI. The goal is to improve detection of these hormone-producing tumors in 5 adults with confirmed biochemical disease. If the scan wor…
Matched conditions: ACROMEGALY
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Diagnosis
Last updated Jun 27, 2026 11:00 UTC
-
Scientists hunt for hidden genes behind pituitary tumors
Knowledge-focused Recruiting nowThis study aims to find new genes that cause pituitary tumors, including those that lead to acromegaly (gigantism) and prolactinomas. Researchers will collect blood and tissue samples from up to 10,000 people with these tumors and their family members. By analyzing DNA, they hope…
Matched conditions: ACROMEGALY
Sponsor: Barts & The London NHS Trust • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC